Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives $60.73 Consensus Target Price from Analysts

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) has been assigned a consensus rating of "Buy" from the twelve brokerages that are currently covering the stock, Marketbeat reports. Ten research analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $60.73.

A number of research firms have commented on MIRM. Robert W. Baird lifted their price objective on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an "outperform" rating in a research note on Thursday, February 27th. HC Wainwright restated a "buy" rating and issued a $73.00 price objective on shares of Mirum Pharmaceuticals in a research note on Monday, May 19th. Raymond James restated a "strong-buy" rating on shares of Mirum Pharmaceuticals in a research note on Tuesday, May 13th. Finally, JMP Securities lifted their price objective on shares of Mirum Pharmaceuticals from $74.00 to $76.00 and gave the company a "market outperform" rating in a research note on Friday, May 9th.

Mirum Pharmaceuticals Stock Down 1.1%

NASDAQ:MIRM traded down $0.52 during midday trading on Friday, hitting $48.46. 675,212 shares of the company were exchanged, compared to its average volume of 513,718. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33. The company has a market capitalization of $2.40 billion, a PE ratio of -23.99 and a beta of 0.95. Mirum Pharmaceuticals has a fifty-two week low of $25.73 and a fifty-two week high of $54.23. The company has a fifty day simple moving average of $42.77 and a 200 day simple moving average of $44.80.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.30) EPS for the quarter, beating analysts' consensus estimates of ($0.35) by $0.05. The company had revenue of $111.59 million for the quarter, compared to analyst estimates of $98.47 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. Mirum Pharmaceuticals's quarterly revenue was up 61.2% on a year-over-year basis. During the same period in the previous year, the business posted ($0.54) earnings per share. As a group, equities analysts anticipate that Mirum Pharmaceuticals will post -1.43 earnings per share for the current fiscal year.

Insider Transactions at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 57,606 shares of the company's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $44.35, for a total value of $2,554,826.10. Following the sale, the senior vice president now owns 4,841 shares of the company's stock, valued at $214,698.35. This represents a 92.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Peter Radovich sold 7,879 shares of the company's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $44.21, for a total transaction of $348,330.59. Following the completion of the sale, the chief operating officer now directly owns 18,672 shares in the company, valued at $825,489.12. This trade represents a 29.67% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 92,764 shares of company stock worth $4,109,161 over the last ninety days. 14.36% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Mirum Pharmaceuticals

A number of institutional investors have recently modified their holdings of MIRM. CWM LLC raised its position in shares of Mirum Pharmaceuticals by 259.4% in the first quarter. CWM LLC now owns 593 shares of the company's stock valued at $27,000 after buying an additional 428 shares during the last quarter. Jones Financial Companies Lllp raised its position in shares of Mirum Pharmaceuticals by 100.0% in the fourth quarter. Jones Financial Companies Lllp now owns 714 shares of the company's stock valued at $30,000 after buying an additional 357 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Mirum Pharmaceuticals in the fourth quarter valued at approximately $35,000. Comerica Bank raised its position in shares of Mirum Pharmaceuticals by 45.1% in the first quarter. Comerica Bank now owns 895 shares of the company's stock valued at $40,000 after buying an additional 278 shares during the last quarter. Finally, GF Fund Management CO. LTD. acquired a new position in shares of Mirum Pharmaceuticals in the fourth quarter valued at approximately $42,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.